OncoSec Medical Incorporated (NASDAQ:ONCS) dropped 8.4% during mid-day trading on Monday . The company traded as low as $1.16 and last traded at $1.20. Approximately 1,443,409 shares traded hands during trading, an increase of 458% from the average daily volume of 258,877 shares. The stock had previously closed at $1.31.

ONCS has been the subject of a number of recent research reports. Maxim Group reissued a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research report on Tuesday, October 10th. ValuEngine downgraded shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a research report on Monday, October 2nd. Finally, Dawson James reissued a “buy” rating and set a $5.00 price objective on shares of OncoSec Medical in a research report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. OncoSec Medical has a consensus rating of “Buy” and a consensus target price of $5.33.

The stock’s market cap is $25.40 million. The firm’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.07.

TRADEMARK VIOLATION NOTICE: “OncoSec Medical Incorporated (ONCS) Shares Down 8.4%” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/16/oncosec-medical-incorporated-oncs-shares-down-8-4.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Receive News & Stock Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related stocks with our FREE daily email newsletter.